Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9007895 | International Immunopharmacology | 2005 | 10 Pages |
Abstract
Secretory phospholipase A2 (sPLA2) enzymes have been implicated in the pathogenesis of human inflammatory bowel disease (IBD). In this study we compared the efficacy of a potent, new and highly selective inhibitor of group IIa human sPLA2 enzyme (5-(4-benzyloxyphenyl)-4S-(7-phenylheptanoylamino)-pentanoic acid; sPLA2I), with that of sulfasalazine, in a rat model of trinitrobenzene sulfonic acid (TNBS)-induced colitis. Following a single oral dose of sPLA2I (5 mg/kg), pharmacoactive levels of drug were detected in the serum within 15 min and for up to 24 h by liquid chromatography mass spectrometry analysis. Rats treated with sPLA2I (5 mg/kg/day) prior to induction of colitis were significantly healthier than TNBS-alone rats, as shown by reduced mortality, improved food intake and increased body weight, and significantly reduced colon myeloperoxidase levels, edema, tumour necrosis factor-α levels, and colon macroscopic pathology scores after 8 days. Rats pretreated with sulfasalazine (100 mg/kg/day) also had reduced disease expression markers similar to the sPLA2I, but exhibited no improvement in colon edema. This study supports a role for the group IIa sPLA2 enzyme in pathology associated with the TNBS rat model of IBD, and suggests a possible therapeutic application for selective inhibitors of group IIa sPLA2 inhibitors in the treatment of IBD.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Trent M. Woodruff, Thiruma V. Arumugam, Ian A. Shiels, Michelle L. Newman, Paul A. Ross, Robert C. Reid, David P. Fairlie, Stephen M. Taylor,